Silver Book Fact

Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placebo
by 40% to 55%.

ASPECT (Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis) Group. Effect of Long- Term Oral Anticoagulant Treatment on Mortality and Cardiovascular Morbidity After Myocardial Infarction. Lancet. 1994; 343(8896): 499-503. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2991458-3/abstract

Reference

Title
Effect of Long- Term Oral Anticoagulant Treatment on Mortality and Cardiovascular Morbidity After Myocardial Infarction
Publication
Lancet
Publication Date
1994
Authors
ASPECT (Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis) Group
Volume & Issue
Volume 343, Issue 8896
Pages
499-503
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.  
  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.